Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures
Efficacy of Kerecis Omega 3 Versus Standard of Care in Patients With Chronic Leg Ulcerations - a Randomized Trial With a New In-wound Split Design Approach
Chronic leg ulcerations are a great burden for patients and the medical system alike. Frequent outpatient consultations with associated treatment costs and travel costs for the patient as well as psychosocial burdens remain an unmet problem in chronic wound care. There is an increasing need for definitive treatment of especially chronic venous and multifactorial chronic leg ulceration where arterial intervention is not a treatment option.
Minimal invasive surgical interventions that do not require skin grafting can be performed under local anesthesia in an outpatient setting even in multimorbid patients.
Kerecis Omega3 Wound is intact decellularized fish skin. The fish skin sheets contain fat, protein, elastin, glycans and other natural skin elements and it can be an effective treatment option in chronic leg ulcerations and is licensed for this use as a medical product in Switzerland. However, limited data without inter-wound bias is available for the use of Kerecis Omega 3 in chronic leg ulcerations.
In this study the investigators propose to investigate the efficacy of Kerecis Omega 3 according to objective wound surface measurements using standardized digital photographs in patients with chronic leg ulcerations. Efficacy will be evaluated against standard of care wound debridement.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Any chronic leg ulcer > 4 weeks duration with delayed wound healing (reduction of wound surface of less than 40-50% within 4 weeks under adequate local therapy) without underlying treatable medical conditions
- Ulcer area at between 5cm2 and 60cm2
- Bacterial swab sampling prior to study
- Written study informed consent
Exclusion Criteria:
- History of Fish allergy or proven Fish allergy
- Pregnant or breast-feeding women
- Intention to become pregnant during the course of the study
- Wound not suitable for dressing: inflammation, fibrin coatings
- Inability to understand the study consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Kerecis Omega 3
|
Decellularized intact fish skin developed for the management of chronic wounds
|
|
Active Comparator: Surgical debridement
|
Superficial sharp surgical debridement technique
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in ulcer surface area
Time Frame: 12 weeks
|
Change in ulcer surface area as assessed by standardized photography and digital imaging.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in patient quality of life
Time Frame: 2, 4, 6 and 12 weeks
|
Change in patient quality of life as assessed by the Wound-QoL questionnaire score, ranging from 0 to 4, with higher scores indicating a worse quality of life.
|
2, 4, 6 and 12 weeks
|
|
Change in wound microbiota as assessed by alpha diversity of the microbial composition
Time Frame: 2, 4, 6 and 12 weeks
|
Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by alpha diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species
|
2, 4, 6 and 12 weeks
|
|
Change in wound microbiota as assessed by beta diversity of the microbial composition
Time Frame: 2, 4, 6 and 12 weeks
|
Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by beta diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species.
|
2, 4, 6 and 12 weeks
|
|
Change in ulcer surface area
Time Frame: 2, 4, 6 and 12 weeks
|
Change in ulcer surface area as assessed by standardized photography and digital imaging.
|
2, 4, 6 and 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events
Time Frame: 12 weeks
|
Cumulative incidence of treatment-related adverse events
|
12 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Simon Bossart, MD, Department of dermatology, University Hospital Inselspital, Bern
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kerecis-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.